ClinicalTrials.gg
CompletedNCT06671873Updated Jul 31, 2025

Study on Mass Balance of [14C]HMPL-306(Isocitrate Dehydrogenase Inhibitor) in Healthy Chinese Adult Male Subjects

A Phase 1 interventional study of 100 µCi [14C] HMPL-306 in Mass Balance Study, sponsored by Hutchmed. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Hutchmed · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of [14C]HMPL-306

Read the detailed description
  • To quantitatively analyze the total radioactivity in excreta after oral administration of [14C]HMPL-306 in healthy subjects, obtain the data on human radioactivity excretion rate and determine the main excretion pathways;
  • To obtain the radioactive metabolite profile in plasma, urine, and feces after oral administration of [14C]HMPL-306 in healthy subjects, to identify the main metabolites and to determine the metabolism and elimination pathways;
  • To quantitatively analyze the total radioactivity in whole blood and plasma in healthy subjects after oral administration of [14C]HMPL-306, to obtain the pharmacokinetics of total radioactivity in plasma and to investigate the distribution of total radioactivity in whole blood and plasma;
02

Conditions studied

  • Mass Balance Study
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are fully informed about the contents, procedures and possible adverse reactions of the study, voluntarily sign the form, and are able to communicate well with investigators and to complete all study procedures specified in the protocol;
  2. Healthy male subjects who are 18 to 45 years (inclusive) at the time of signing the informed consent form.;
  3. Weight ≥50 kg, and (BMI) between 19 - 26 kg/m2 (inclusive);
  4. Subjects must promise to have no pregnancy plan or sperm donation plan and to use condoms during sexual intercourse from signing the informed consent form until 180 days after end of the study treatment. If the sexual partner is a female of , a highly effective method of should be also used (see Appendix 1 for more information).

Exclusion criteria

Exclusion Criteria:

  1. History of serious allergy (e.g., drug allergy) and acute allergic rhinitis or food allergy within two weeks prior to screening;
  2. Subjects with a history or clinical manifestation of metabolic/endocrine, hepatic, renal, hematologic, pulmonary, immunologic, cardiovascular, gastrointestinal, genitourinary, neurologic, or psychiatric diseases within 3 months prior to and during the screening period (judged by investigators);
  3. Previous history of hypertension;
  4. Subjects who are positive for surface antigen (HBsAg), anti- virus (HCV) antibody, anti- (HIV) antibody, or anti-treponema pallidum antibody;
  5. Smoking more than 10 cigarettes daily within 3 months prior to the screening and inability to refrain from smoking completely during the study period;
  6. Regular alcohol consumption within 6 months prior to the study, i.e., drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine), or positive alcohol breath at screening;
  7. Presence of drug abuse or dependence, or positive urine screen for drugs of abuse;
  8. Subjects who have poor venous access, and have a fear of needles, hemophobia or difficulty in blood collection;
  9. Having participated in clinical trials for other drugs within 3 months prior to the screening;
  10. Workers who need to be exposed to radioactive condition for a long term; or those who have significant radiation exposure (≥2 times of chest/abdominal computerised tomography (CT), or ≥3 times of other kinds of X-ray examinations) within 1 year prior to administration, or have participated in the radiopharmaceutical labeling study;
  11. Subjects who have been vaccinated within 30 days prior to administration and who have a plan for vaccination within 2 weeks after administration;
  12. According to the investigator's judgment, the subjects have any other disease or status that may affect the normal completion of the study or the evaluation of the study data, or have any other condition that is not suitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    100 µCi [14C] HMPL-306

    After an overnight fasting of at least 10 hours, subjects will receive \[14C\] HMPL-306 containing 250 mg HMPL-306 (approximately 100 μCi radioactivity) 30 minutes after start of breakfast (must be completed within 30 minutes) and ensure that all of the drug is taken within 10 minutes.

    Drug: 100 µCi [14C] HMPL-306

Interventions

  • Drug100 µCi [14C] HMPL-306

    D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose

    Also known as: 100 µCi [14C] HMPL-306 suspension

06

What researchers measure

Primary outcomes

  1. Human Mass Balance

    Recovery and cumulative recovery of total radioactivity in excreta (urine and feces).

    Time frame: Day1~Day29

  2. Human Mass Balance

    Percentage of the unchanged drug and its metabolites in plasma to total radioactivity exposure levels in plasma;

    Time frame: Day-1~Day29

  3. Human Mass Balance

    Percentage of the unchanged drug and its metabolites in urine and feces to the administered dose;

    Time frame: Day-1~Day29

  4. Human Mass Balance

    Identification of major metabolites in plasma, urine and feces.

    Time frame: Day-1~Day29

  5. Human Mass Balance

    PK parameters of total radioactivity in the plasma; Ratio of total radioactivity concentration in whole blood/plasma at different time points.

    Time frame: Day-1~Day29

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
    Jinan, China
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 4, 2024
StartActual
Nov 26, 2024
Primary completionActual
Feb 28, 2025
CompletionActual
Jul 2, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06671873
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Nov 26, 2024
Primary completion
Feb 28, 2025
Completion
Jul 2, 2025
Last update
Jul 31, 2025

Study contacts

Wei Zhao, offices director
principal investigator · The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion